Toxicidad
S f ib
Axitinib (n=359)
ora en
(n=355)
Dose interruptions, %
76.9
80.3
Due to AEs, %
54.0
63.1
Patients with dose increase, %
%
36.8
NA
Patients with dose decrease,
30.6
52.1
Median relative dose intensity, %
98.6
91.7
Discontinuations due to treatment-related AEs, %*
3.9
8.2
*AEs as determined by investigators.
29
Rini BI et al. ASCO 2011; Abstract 4503
